A [NACHC fact sheet](https://www.nachc.org/wp-content/uploads/2025/10/NACHC-Vision-Services-Expansion-Fact-Sheet_V4.pdf) reported that 26% of U.S. community health centers offered vision services and 3% of their patients got eye care each year. That gap is a reason to look into vision care. The decision rests on your own clinical, money, staffing, and governance facts. No FDA authorization or vendor case study can replace them.
Should your FQHC add vision care? Five questions to decide
Five questions on local need, staff, scope, payers, referrals, AI screening, privacy, access, cost, and governance before you decide to pilot, defer, or skip vision care.
A NACHC fact sheet reported that 26% of U.S. community health centers offered vision services, and 3% of patients got eye care each year. That gap is a reason to look into vision care. It does not show that your FQHC should launch it. This walkthrough lists the local questions that FDA clearance or a vendor case study cannot answer.
The 5 questions
Question 1
Can we build a decision-ready local scenario?
Some eligible optometry encounters may be paid under an applicable FQHC PPS methodology. Confirm the proposed service, practitioner, patient, payer, same-day rules, and site-specific rate before treating an encounter as payable.
The worksheet demonstrates that 3,600 encounters multiplied by a $300 input equals $1.08M in modeled gross PPS payments. It is arithmetic—not an observed result, a typical rate, or a forecast. ACU's dated survey had 39 anonymous respondents (about 9% of the workforce) and does not establish a capacity target.
Open the planning worksheet and replace every pre-filled illustration with current written evidence: role budgets, benefits, vendor and build-out quotes, financing, applicable rate, payer mix, eligibility, denials, collections, ramp, occupancy, administration, and compliance costs. The $250, $300, and $400 comparisons are inputs—not worst, conservative, floor, or typical cases.
No generic output threshold makes the case decision-ready. Finance and operations owners should reconcile the worksheet to an audited local pro forma, test downside and break-even conditions, identify omitted costs, and document who owns each uncertain input before board review.
Use this tool
Vision planning worksheet
Editable illustrative inputs and transparent arithmetic. Replace every value with current local documentation; outputs are not forecasts or guaranteed returns.
Question 2
Can we use AI screening for diabetic retinopathy?
FDA records identify several diabetic-retinopathy AI devices, but authorization does not establish deployability at a particular FQHC. Each configuration still needs clinical, evidence, hardware, workflow, payer, integration, privacy, security, accessibility, procurement, service, and total-cost review.
FDA's DEN180001 record documents an April 11, 2018 De Novo decision for IDx-DR, now marketed as LumineticsCore. FDA's K200667 record documents an August 3, 2020 decision for EyeArt. These dated records establish evaluated indications, not historical rankings or comparative superiority.
FDA records for AEYE-DS include a portable-camera configuration (K240058). Portability does not establish mobile-site or home-visit feasibility; validate imageability, training, lighting, connectivity, infection control, licensing, accessibility, escalation, referral capacity, integration, privacy, security, coverage, service, and total cost.
Historical fee examples for CPT 92229, 92228, and 92227 do not establish current coverage or payment for a particular payer, device, patient, site, or workflow. Verify the current fee schedule, coding, coverage, medical-necessity, and contract terms directly before underwriting a deployment.
A Digital Diagnostics case study about Cahaba Medical Care reported findings from one implementation. It is vendor-authored, dated case evidence; do not multiply its reported detection share across your panel or treat it as an expected clinical or financial outcome.
JAMA Network Open published the DRES-POCAI protocol at San Ysidro Health. It describes a planned randomized study, not completed outcomes; recheck trial status and publications before citing screening completion, diagnostic yield, referral completion, equity, policy, coverage, payment, or return.
Use the AI comparison wizard to organize diligence questions, not to delegate the decision. Verify the FDA record, indication, independent performance evidence, hardware, training, EHR integration, privacy, accessibility, escalation, coverage, pricing, and contract terms directly.
Use this tool
AI Selection Wizard
Four-question comparison aid with source links and explicit diligence questions. It is not a clinical, procurement, reimbursement, or payback recommendation.
Question 3
Can we recruit an OD without NHSC eligibility?
The cited FY2026 HRSA NHSC Loan Repayment guidance did not list optometry among eligible disciplines. AOA has supported proposed inclusion through NHSC-improvement legislation. Recheck the current discipline list, award terms, application cycle, site status, and bill status; the dated record does not prove the cause or size of a local recruiting gap.
The ACU 2023 FQHC Optometry Workforce Survey reported a $155K average among 39 anonymous respondents (about 9% of the workforce) and different rural and urban subgroup averages. That is a useful dated descriptive signal, not proof of a controlled rural premium or a current market rate.
Do not generalize those subgroup averages into an urban-versus-rural pay rule. For recruitment planning, verify the employer's written range and use CA Optometric Association, UC Berkeley / SCCO / Western alumni networks, and the CA AB 407 (2021) scope framework as separate context.
Test recruiting messages rather than assuming they differentiate the role. Candidate research can cover the mission and population, written compensation and benefits, workload, schedule, supervision, referral support, credentialing, FTCA applicability, and the current California scope under AB 407. Verify each claim with accountable HR and legal owners.
If policy advocacy is in scope for your organization, verify the current status of the proposed NHSC Improvement Act, applicable lobbying rules, and internal authorization before acting. Keep advocacy separate from the local workforce and service-line decision.
Use this tool
Advocacy: NHSC + Medi-Cal Rate
Dated policy records to reverify, with source links and organizational-authorization checks kept separate from the local business case.
Question 4
Where will patients come from, and where do charity partners fit?
A local needs and referral-pathway assessment should precede any launch. Public school and charity programs are potential partners to investigate, not a guaranteed patient pipeline.
Vision To Learn and Warby Parker's Pupils Project report California school footprints. These organization-reported counts identify potential partners to investigate; they do not establish current capacity, eligibility, referral completion, coverage, patient conversion, exclusivity, or financial benefit for an FQHC.
A proposed school-to-clinic handoff needs written clinical eligibility, consent, privacy and data-sharing, referral ownership, escalation, accessibility, capacity, cost, and follow-up terms. Use the MOU guide as a prompt and obtain clinical, legal, compliance, and partner review before relying on the pathway.
VSP Eyes of Hope publishes information about charitable and mobile programs. Its reported footprint does not establish current availability, eligibility, capacity, cost, referral ownership, coverage, or fit; obtain current written terms directly.
For surgical safety valve in the Bay Area, Lions Eye Foundation of CA-NV (711 Van Ness, SF) provides free comprehensive ophthalmic care including cataract surgery for uninsured patients. For Medicare-eligible 65+ uninsured patients, AAO EyeCare America's Senior Program gives free volunteer ophthalmologist exams.
For pediatric vision, review the current DHCS vision-benefit rules and the applicable plan, vendor, authorization, replacement, materials, and billing rules. Do not assume pediatric operations are simpler or that a child's visit will convert other family members into payable encounters; measure the local referral pathway.
Use this tool
Charity Partner Directory
Nine public partner records to investigate. Reverify eligibility, capacity, geography, consent, privacy, referral ownership, escalation, accessibility, cost, follow-up, and current terms directly.
Question 5
What would an operating plan include?
Move to implementation planning only after accountable owners validate the clinical need, local pro forma, workforce plan, coverage and billing, privacy, accessibility, referral safety, procurement, compliance, and governance gates. The Vision Service Line Launch Playbook is a sequencing checklist; its dates and volumes are editable planning aids, not a promise that a launch is safe or feasible in 90 days.
Use the risk register as a prompt, then add site-specific risks and named owners. Recruitment, payer and vendor rules, adoption, dispensary assumptions, referral completion, clinical escalation, accessibility, privacy, and omitted costs require local evidence; a generic mitigation does not close a gate.
Set Year-1 measures from your own measured baseline and a plan with owners: access, completed referrals, safety, patient experience, equity, staff workload, denials, collections, total cost, and the applicable quality specification. The old 3,000-encounter, $900K-revenue, 40%-capture, and $700K-margin figures are illustrations—not universal targets or expected outcomes.
Use this tool
Conditional Vision Diligence Sequence
3 phases × 12 editable weekly steps with checklists. 4 planning milestones (Day 30/60/90/365). Risk register, planning worksheet, and AI diligence aid.
What's the cost of waiting?
Waiting has a cost only when a health center has documented unmet need and a feasible alternative it is not pursuing. A vendor case study cannot quantify that cost for another FQHC. Measure your own diabetic-eye-exam completion, referral closure, wait time, diagnostic yield, false-positive pathway, patient preference, and capacity before estimating benefit or harm.
The public evidence establishes access questions, available technologies, example programs, and policy constraints—not that the economics work at your site. Verification against current primary sources and accountable clinical, finance, compliance, operations, privacy, procurement, accessibility, and governance sign-off remain required.
Use the tools to make uncertainty visible, assign owners, and close evidence gaps before deciding whether—and how—to proceed.
What to do this week
- Measure your own diabetic eye exam completion and referral numbers first.
- Name an owner for each open question: clinical, finance, staffing, privacy, and payer rules.
- Treat a no-go, a delay, or a referral partnership as a valid outcome.
Related tools
The complete vision care toolkit on the FQHC Talent platform — interactive components, case studies, masterclass modules, workplace guides, research archive, OKR templates, advocacy actions, and supporting blog posts.
Full Vision Strategy Page
Dated public program records, a scope timeline, population evidence, a small descriptive workforce survey, and explicit local-verification gates. Not a complete inventory or market benchmark.
4 FQHC Vision Case Studies
A vendor-authored Cahaba implementation case, the San Ysidro DRES-POCAI trial protocol, and two documented program examples—with evidence limits.
Vision care guide
Review source limits, local assumptions, and owner-gated planning questions before use.
6 Vision Workplace Guides
Launch Checklist, AI Implementation, Medi-Cal MCO Billing, School-FQHC MOU, Farmworker Vision, Glaucoma Screening Protocol.
How we use data
Understand how sourced facts, local assumptions, illustrative content, and unknowns are separated.
Vision OKR Template
A downloadable draft for owner-gated milestones. Replace any volume, financial, quality, staffing, procurement, or partner target with an approved local baseline and plan.
AI Tracker — Vision Vendors
Source-aware vendor records with editorial screening flags and evidence limits. They are not rankings, endorsements, customer verification, or procurement recommendations.
PPS and Vision Planning Guide
A source-aware guide to PPS questions, workforce evidence, AI diligence, and the local inputs required for a service-line decision.
FDA Authorization + AI Diligence Blog Post
What the dated FDA records establish—and which clinical, payer, workflow, evidence, privacy, security, accessibility, and total-cost questions remain open.
CA Kids' Vision Crisis Blog Post
Only 16% of California Medi-Cal kids got an eye exam — and 47 of 58 counties got worse. Why FQHCs could be one practical access partner.
Sources
- · NACHC 2025 Vision Services Expansion Brief ($630M / 1,070 ODs / 10.7M unserved patients)
- · ACU 2023 FQHC Optometry Workforce Survey (39 anonymous responses, about 9%; descriptive—not a rural-pay rule)
- · FDA De Novo IDx-DR Authorization (DEN180001)
- · Cahaba Medical Care AI Implementation White Paper (one vendor-authored implementation case; do not extrapolate)
- · JAMA Network Open: San Ysidro DRES-POCAI Trial Protocol (NCT06721351)
- · CalMatters: 16% of Medi-Cal Kids Got an Eye Exam (April 2026)
- · NEI / LALES — Los Angeles Latino Eye Study (75% of Latinos with glaucoma undiagnosed)
- · HRSA NHSC FY2026 LRP Application Guidance (optometry NOT eligible)
- · CA SB 1406 (Aanestad, 2008) — OD Glaucoma Scope
- · CA AB 407 (Salas, 2021) — OD Anterior Segment + Oral Rx + Immunizations
- · HRSA BPHC Compliance FAQs (Section 330 eyewear exclusion)